Highest-materiality recent filing
Cue Biopharma Q1 net loss $5.2M; appoints new CEO, $30M private placement, CUE-221 license
Net loss $5.2M ($1.08 EPS) vs $12.3M loss in Q1 2025; revenue $5.7M from Boehringer collaboration.
Cue Biopharma licenses ex-China rights to anti-IgE mAb Ascendant-221; raises $30M; appoints new CEO
License with Ascendant Health Sciences: $15M upfront, up to $676.5M milestones, tiered high-single-to-low-double-digit royalties on ex-China sales.
Cue Biopharma files 1-for-30 reverse stock split to maintain Nasdaq listing
1-for-30 reverse stock split effective 5:00 PM ET on April 23, 2026; no fractional shares, cash in lieu.
Cue Biopharma stockholders approve reverse stock split with ratio 1:30 to 1:50
Elected Pasha Sarraf, Peter A. Kiener, Frank Morich, Pamela Garzone, Patrick Verheyen, and Jill Broadfoot to the Board.
Cue Biopharma achieves preclinical milestone with Boehringer Ingelheim; $7.5M payment due May 2026
Boehringer Ingelheim approved selection of first compound for lead optimization under April 2025 collaboration.
Cue Biopharma CEO Usman Azam resigns; Lucinda Warren named Interim CEO
Usman Azam resigned as President, CEO and Board member effective March 26, 2026.
Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M
Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.
Cue Biopharma sets 2026 annual meeting for April 13; shareholder deadlines on Feb 28.
Annual meeting date: April 13, 2026.
Cue Biopharma appoints CBO Lucinda Warren as CFO effective Feb 9, 2026
Lucinda Warren, previously CBO, named Chief Financial & Business Officer; assumes principal financial/accounting officer duties.
Cue Biopharma raises ~$10M in dilutive public offering; cash runway through Q1 2027
Gross proceeds ~$10M from 35.7M shares/pre-funded warrants and 17.9M warrants at $0.28 combined offering price.
Cue Biopharma posts updated corporate presentation on website; no specific new facts disclosed
Company made an updated corporate presentation available on its website on November 24, 2025.
Cue Biopharma CMO Matteo Levisetti to depart Nov 28; gets $556,838 severance
Chief Medical Officer Matteo Levisetti will terminate employment effective November 28, 2025.
Cue Biopharma Q3 net loss $0.07/sh; ImmunoScape deal $15M upfront; new CEO
Q3 net loss $7.45M ($0.07 EPS); revenue $2.15M (down 36% YoY); cash $11.7M (down 48% from Dec 2024).
Cue Biopharma licenses CUE-100 series to ImmunoScape; receives $15M cash and 40% equity
Collaboration with ImmunoScape to develop 'Seed-and-Boost' TCR-T cell therapy for solid tumors using CUE-100 series.
Cue Biopharma appoints Usman Azam as CEO, succeeding Daniel Passeri who transitions to advisor
Usman Azam appointed President and CEO effective Sept 29, 2025; succeeds Daniel Passeri who retires and becomes strategic advisor.
Cue Biopharma Q2 net loss $8.5M; BI deal with $12M upfront, $345M milestones
Net loss $8.5M ($0.09/share) vs $10.2M in Q2 2024; collaboration revenue $3.0M.
Cue Biopharma reduces monthly rent 37% and extends Boston lease to April 2028
Monthly rent cut from $235,884 to $147,546, effective June 30, 2025.
Cue Biopharma CFO resigns, elects Jill Broadfoot to board, increases authorized shares to 310M
CFO Kerri-Ann Millar resigns effective June 13, 2025; CEO Daniel Passeri will be interim principal financial and accounting officer.
On June 4, 2025, Jill Broadfoot was appointed to the board of directors (the “Board”) of Cue Biopharma, Inc. (the “Company”), the Audit Committee of the Board, and the Corporate Governance and Nominating Committee of the Board
On June 4, 2025, Kerri-Ann Millar notified the Company that she is resigning from her position as Chief Financial Officer, effective June 13, 2025.
Effective June 13, 2025, Daniel R. Passeri, the Company’s Chief Executive Officer, will serve as the Company’s principal financial and accounting officer on an interim basis until a new principal financial and accounting officer is designated.
Max materiality 0.85 · Median 0.68 · Most common event other_material